Organogenesis Holdings Inc.
ORGOHealthcare|Drug Manufacturers - Specialty & Generic|US
$0.81
-0.03 (-3.18%)
DCF Value
$3.83
Tangible Book / Share
$1.79
Cash / Share
$0.17
Financials
Financial Snapshot
Market Cap
$104.6M
Enterprise Value
$147.8M
Revenue (TTM)
$351.5M
Net Income (TTM)
-$144.6M
Cash & Investments
$21.3M
Net Cash
-$43.2M
Free Cash Flow (TTM)
-$64.0K
Operating CF (TTM)
$10.3M
Debt/Equity
0.54
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.0M | $125.9K | $21.3M | $60.2M | $84.4M | $113.9M | $102.5M | $104.3M | $135.6M | $93.7M | $21.3M | |
| Operating Cash Flow | -$562.2K | -$586.6K | -$60.7M | -$33.5M | $5.5M | $62.0M | $24.9M | $30.9M | $14.2M | -$10.3M | $10.3M | |
| Free Cash Flow | -$1.9M | -$3.0M | -$62.6M | -$39.8M | -$12.2M | $30.8M | -$9.0M | $6.6M | $4.2M | -$24.5M | -$64.0K | |
| Capital Expenditure | -$1.4M | -$2.4M | -$1.9M | -$6.2M | -$17.7M | -$31.2M | -$33.9M | -$24.4M | -$10.0M | -$14.2M | -$10.4M | |
| Financing Cash Flow | $311.5M | -$327.6K | $81.6M | $78.7M | $42.5M | -$1.0M | -$2.2M | -$5.5M | $27.6M | -$17.4M | -$41.0M |
R&D Spending
R&D (TTM)
$51.7M
R&D Intensity
14.7%
R&D Growth vs Prior
+16.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $193.4M | $261.0M | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | $563.0M | $351.5M | |
| R&D Expense | $0.00 | $0.00 | $10.7M | $14.8M | $20.1M | $30.7M | $39.8M | $44.4M | $50.3M | $44.5M | $51.7M | |
| R&D % of Revenue | — | — | 5.6% | 5.7% | 5.9% | 6.6% | 8.8% | 10.2% | 10.4% | 7.9% | 14.7% | |
| SG&A | $208.7K | $4.6M | $162.0M | $200.1M | $204.2M | $250.2M | $283.8M | $269.8M | $294.5M | $326.2M | $264.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $193.4M | $261.0M | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | $563.0M | $351.5M | |
| Cost of Revenue | $208.7K | $4.6M | $68.8M | $75.9M | $87.3M | $114.2M | $105.0M | $106.5M | $115.7M | $137.5M | $111.7M | |
| Gross Profit | -$208.7K | -$4.6M | $124.6M | $185.0M | $251.0M | $353.2M | $345.9M | $326.7M | $366.3M | $425.5M | $194.3M | |
| R&D | $0.00 | $0.00 | $10.7M | $14.8M | $20.1M | $30.7M | $39.8M | $44.4M | $50.3M | $44.5M | $51.7M | |
| SG&A | $208.7K | $4.6M | $162.0M | $200.1M | $204.2M | $250.2M | $283.8M | $269.8M | $294.5M | $326.2M | $264.4M | |
| Operating Income | $208.7K | -$4.6M | -$51.6M | -$29.9M | $26.7M | $72.2M | $22.3M | $12.5M | -$1.3M | $55.9M | -$80.3M | |
| Interest Expense | $5.6M | $8.0M | $10.9M | $9.0M | $11.3M | $7.2M | $2.0M | $2.2M | $1.5M | $0.00 | -$61.0K | |
| Pretax Income | -$208.7K | -$2.1M | -$64.7M | -$38.6M | $17.8M | $63.1M | $20.3M | $10.4M | -$2.8M | $47.0M | -$85.5M | |
| Net Income | -$208.7K | -$2.1M | -$64.8M | -$38.7M | $17.2M | $94.2M | $15.5M | $4.9M | $861.0K | $37.0M | -$144.6M | |
| EPS (Diluted) | -0.02 | -0.03 | -0.94 | -0.44 | 0.15 | 0.70 | 0.12 | 0.04 | -0.01 | 0.15 | -1.19 | |
| EBITDA | $7.1M | -$2.1M | -$46.9M | -$19.7M | $37.2M | $87.0M | $40.3M | $36.0M | $15.8M | $73.9M | -$59.4M | |
| Shares Out. (M) | 8.58 | 63.88 | 69.32 | 92.84 | 111.36 | 133.66 | 132.38 | 132.75 | 131.67 | 130.25 | 128.99 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.0M | $125.9K | $21.3M | $60.2M | $84.4M | $113.9M | $102.5M | $104.3M | $135.6M | $93.7M | $21.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $1.4M | $294.4K | $71.1M | $125.6M | $174.3M | $227.0M | $222.6M | $225.0M | $285.9M | $362.2M | $158.1M | |
| Total Assets | $311.4M | $312.8M | $163.7M | $220.7M | $290.2M | $443.3M | $449.4M | $460.0M | $497.9M | $598.7M | $368.9M | |
| Total Current Liabilities | $478.4K | $3.9M | $66.4M | $59.9M | $68.2M | $82.7M | $75.0M | $80.5M | $77.5M | $100.1M | $47.6M | |
| Long-Term Debt | $0.00 | $0.00 | $39.1M | $83.1M | $53.0M | $70.8M | $66.2M | $60.7M | $0.00 | $50.7M | $55.2M | |
| Total Liabilities | $11.3M | $14.8M | $116.6M | $165.1M | $148.4M | $201.9M | $183.7M | $181.4M | $112.6M | $164.8M | $106.2M | |
| Stockholders' Equity | $300.1M | $298.0M | $47.0M | $55.6M | $141.8M | $241.3M | $265.7M | $278.7M | $385.3M | $433.9M | $119.7M | |
| Retained Earnings | -$233.9K | -$2.3M | -$130.2M | -$171.0M | -$155.0M | -$60.8M | -$45.3M | -$41.0M | -$40.1M | -$3.1M | -$182.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$562.2K | -$586.6K | -$60.7M | -$33.5M | $5.5M | $62.0M | $24.9M | $30.9M | $14.2M | -$10.3M | $10.3M | |
| Capital Expenditure | -$1.4M | -$2.4M | -$1.9M | -$6.2M | -$17.7M | -$31.2M | -$33.9M | -$24.4M | -$10.0M | -$14.2M | -$10.4M | |
| Free Cash Flow | -$1.9M | -$3.0M | -$62.6M | -$39.8M | -$12.2M | $30.8M | -$9.0M | $6.6M | $4.2M | -$24.5M | -$64.0K | |
| Investing Cash Flow | -$310.0M | -$14.9M | -$1.9M | -$6.2M | -$23.5M | -$31.2M | -$33.9M | -$24.4M | -$10.0M | -$14.2M | -$6.8M | |
| Financing Cash Flow | $311.5M | -$327.6K | $81.6M | $78.7M | $42.5M | -$1.0M | -$2.2M | -$5.5M | $27.6M | -$17.4M | -$41.0M | |
| Issuance of Stock | $303.8M | -$427.6K | $92.0M | $50.3M | $64.7M | $2.2M | $0.00 | $0.00 | $0.00 | $157.0K | $1.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$6.8M | $0.00 | $0.00 | $0.00 | $0.00 | -$25.5M | $0.00 | $0.00 | |
| Net Debt Issuance | $12.0M | $100.0K | $1.1M | $37.2M | -$15.9M | -$2.0M | -$3.0M | -$5.2M | -$67.6M | -$1.2M | -$10.5M | |
| Stock Based Comp. | $473.0K | $919.0K | $1.1M | $936.0K | $1.7M | $3.9M | $6.6M | $9.0M | $10.6M | $13.3M | $13.8M | |
| Net Change in Cash | $914.0K | -$914.2K | $19.0M | $39.0M | $24.4M | $29.7M | -$11.2M | $1.0M | $31.8M | -$41.8M | -$37.4M |
Dilution Tracker
Shares Outstanding
129M
5-Year Share Growth
+17.0%
Stock Issuance (TTM)
$1.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 8.58 | 63.88 | 69.32 | 92.84 | 111.36 | 133.66 | 132.38 | 132.75 | 131.67 | 130.25 | 128.99 | |
| Change vs Prior % | — | 644.5% | 8.5% | 33.9% | 19.9% | 20.0% | -1.0% | 0.3% | -0.8% | -1.1% | -1.0% | |
| Stock Issuance | $303.8M | -$427.6K | $92.0M | $50.3M | $64.7M | $2.2M | $0.00 | $0.00 | $0.00 | $157.0K | $1.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$6.8M | $0.00 | $0.00 | $0.00 | $0.00 | -$25.5M | $0.00 | $0.00 | |
| Stock Based Comp. | $473.0K | $919.0K | $1.1M | $936.0K | $1.7M | $3.9M | $6.6M | $9.0M | $10.6M | $13.3M | $13.8M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 64.4% | 70.9% | 74.2% | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% | 55.3% | |
| Operating Margin % | — | — | -26.7% | -11.4% | 7.9% | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% | -22.8% | |
| Net Margin % | — | — | -33.5% | -14.8% | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% | -41.1% | |
| EBITDA Margin % | — | — | -24.3% | -7.6% | 11.0% | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% | -16.9% | |
| FCF Margin % | — | — | -32.4% | -15.2% | -3.6% | 6.6% | -2.0% | 1.5% | 0.9% | -4.3% | -0.0% | |
| ROE % | -0.1% | -0.7% | -137.8% | -69.6% | 12.2% | 39.0% | 5.8% | 1.8% | 0.2% | 8.5% | -47.3% | |
| ROA % | -0.1% | -0.7% | -39.6% | -17.5% | 5.9% | 21.3% | 3.5% | 1.1% | 0.2% | 6.2% | -39.2% | |
| ROIC % | -0.1% | -1.4% | -50.5% | -18.2% | 10.7% | 19.2% | 4.4% | 1.5% | 0.1% | 8.5% | -24.3% | |
| R&D / Revenue % | — | — | 5.6% | 5.7% | 5.9% | 6.6% | 8.8% | 10.2% | 10.4% | 7.9% | 14.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 34.9% | 29.6% | 38.2% | -3.5% | -3.9% | 11.3% | 16.8% | |
| Gross Profit | 0.0% | -2100.2% | 2814.4% | 48.5% | 35.6% | 40.7% | -2.1% | -5.6% | 12.1% | 16.2% | |
| Operating Income | 0.0% | -2300.2% | -1022.8% | 42.1% | 189.4% | 170.5% | -69.1% | -43.8% | -110.2% | 4454.6% | |
| Net Income | 0.0% | -903.3% | -2996.2% | 40.3% | 144.5% | 446.6% | -83.5% | -68.2% | -82.6% | 4201.0% | |
| EPS (Diluted) | 0.0% | -35.0% | -2765.9% | 53.2% | 134.1% | 366.7% | -82.9% | -68.9% | -126.8% | 1600.0% | |
| Operating Cash Flow | 94.5% | -4.3% | -10254.3% | 44.8% | 116.3% | 1033.9% | -59.9% | 24.4% | -54.0% | -172.6% | |
| Free Cash Flow | 82.0% | -56.6% | -1977.8% | 36.5% | 69.3% | 351.9% | -129.4% | 172.5% | -36.3% | -685.7% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 37.8% | 35.7% | 53.1% | 29.3% | 11.6% | 13.3% | -11.4% | |
| SG&A Expense | 0.0% | 2100.2% | 3427.2% | 23.5% | 2.1% | 22.5% | 13.4% | -5.0% | 9.2% | 10.8% | |
| Total Assets | 74715.7% | 0.4% | -47.7% | 34.8% | 31.5% | 52.7% | 1.4% | 2.4% | 8.2% | 20.3% | |
| Book Value / Share | 0.0% | -86.7% | -85.4% | -12.2% | 119.9% | 42.9% | 8.6% | 4.0% | 37.8% | 17.0% | |
| Debt | -100.0% | 0.0% | 231.8% | 69.8% | -15.7% | 56.1% | -6.4% | -3.6% | -63.7% | 206.7% | |
| Diluted Shares | 0.0% | 644.5% | 8.5% | 33.9% | 19.9% | 20.0% | -1.0% | 0.3% | -0.8% | -1.1% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High12.66 / 32.38 / 108.49
P/S0.30
10Y Low / Med / High0.78 / 1.71 / 3.62
P/B0.88
10Y Low / Med / High0.28 / 2.13 / 14.88
EV/EBITDAAt Loss
10Y Low / Med / High9.21 / 13.84 / 21.80
EV/Revenue0.42
10Y Low / Med / High0.68 / 1.87 / 3.81
P/FCFAt Loss
10Y Low / Med / High38.55 / 81.91 / 100.90
Intrinsic Value Models (per share)
DCF Value
$3.83
Tangible Book / Share
$1.79
Net Current Assets / Share
$0.40
Cash / Share
$0.17
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -401.23 | -302.44 | -10.80 | -10.93 | 47.06 | 12.66 | 22.42 | 108.49 | -450.70 | 32.38 | -0.69 | |
| P/S Ratio | 0.00 | 0.00 | 3.62 | 1.71 | 2.40 | 2.54 | 0.78 | 1.24 | 0.87 | 1.17 | 0.30 | |
| P/B Ratio | 0.28 | 2.13 | 14.88 | 8.03 | 5.72 | 4.91 | 1.32 | 1.93 | 1.09 | 1.51 | 0.88 | |
| EV/EBITDA | 11.62 | -311.09 | -15.73 | -24.67 | 21.80 | 13.84 | 9.21 | 15.31 | 20.88 | 9.41 | -2.49 | |
| EV/Revenue | 0.00 | 0.00 | 3.81 | 1.87 | 2.40 | 2.58 | 0.82 | 1.27 | 0.68 | 1.24 | 0.42 |
Analyst Estimates & Quality
Altman Z-Score
0.45
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $196.1M | $269.7M | $301.0M |
| Net Income | -$169.9M | -$33.5M | -$26.0M |
| EPS | $-1.38 | $-0.31 | $-0.20 |
| # Analysts (EPS) | 1 | 2 | 2 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Advanced Wound care | $294.6M | $430.8M | $422.2M | $405.5M | $453.6M | — |
| Surgical and Sports Medicine | $43.7M | $37.2M | $28.7M | $27.6M | $28.4M | — |
| Grant | — | — | — | — | — | $1.1M |
| Product | — | — | — | — | — | $563.0M |